MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
about
Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapyRegulation of mitochondrial functions by protein phosphorylation and dephosphorylationTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerBalance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLCInvolvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.Protein tyrosine phosphatases as potential therapeutic targets.Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations.APC selectively mediates response to chemotherapeutic agents in breast cancer.Phosphotyrosine Substrate Sequence Motifs for Dual Specificity PhosphatasesDownregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancerMitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease.In vivo identification of novel STAT5 target genesDual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase PathwayProteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cellsMMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway.Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy.The dual-specificity MAP kinase phosphatases: critical roles in development and cancer.MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.Mitogen-activated protein kinase phosphatase-1 represses c-Jun NH2-terminal kinase-mediated apoptosis via NF-kappaB regulationUnphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer.DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells.MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer.High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response.MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.Decreased total MKP-1 protein levels predict poor prognosis in breast cancer.NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway.l-Glutamine Attenuates DSS-Induced Colitis via Induction of MAPK Phosphatase-1.
P2860
Q26745758-02928E82-6B9E-462D-8A5E-77B97CCC8E32Q26752880-798AD6F6-94C0-46EB-865F-2DB778AD4992Q28396304-D285932B-7BE5-4CF0-BD12-B0B93D59F7C2Q28478252-064C1D32-E30F-48FD-B808-6D668CD42945Q33776998-E84AA230-7CAC-43F0-9412-E79C03C2DA23Q34140221-14680FDC-0257-49A0-AEB2-49F3C03F5C98Q34295063-5EBC169D-10CB-4FD3-B077-0D24A8892E53Q34998443-59135DC9-7731-4A73-8F8E-0DB195BBEB09Q35655334-78BAAACF-48B0-4038-9F7E-8006112F8540Q35753812-2EC2F22C-EFC6-4DE9-8716-63A72E775F5EQ35911664-BE05F170-4CD4-416F-8040-1D0B6BB1C95BQ36301783-B24F977D-F98E-4501-8102-F1B3855C12FFQ36740156-4853B4FD-71CC-48E1-A281-FD4862B941B1Q36930125-1A86D51C-5038-4586-924B-A52CD45C58E1Q37210693-DA73674D-C653-4412-AEF4-B2EA1F48931DQ37268755-31C447E4-C0FF-4641-A788-A7A9A7E893D7Q37365307-823B2346-87E3-4E9A-B288-37A6131AC919Q37750129-CE1BE2C1-A852-442E-9F12-C4A568A2A5E2Q38810052-828C6AF9-49B5-4F6D-A7E9-69CE689805B2Q38841880-63842474-2038-40E0-9D58-2D733260FA10Q38990407-F7CA43B7-1BF9-4311-92D1-9979272CCFD5Q39089770-1E425E09-9D7A-4132-A0F7-D38126A708E2Q39356827-1F7743F3-FE17-47D8-A3F4-5A8BC90E3CFBQ39648524-6D33074F-493D-4A47-8817-946ECEFD799EQ39977638-8D1EEC9A-404B-4AA0-9664-7E24A08B133CQ40180995-FEFA699F-DA35-49BA-B0BA-E4397A7B46C1Q47107718-6BBA5FE6-05E7-4675-A55F-EBB00FD17C0EQ47163224-3DB9BF72-9E2B-49B9-A37B-38448A2F2869Q47170552-05BDB119-CD09-48A6-A035-CAC88FC84553Q48334668-5D0C8456-5AD2-44C0-8C44-687EF058D00CQ51174191-534BAEB6-8687-4EAF-819B-F88CEDACC9C0Q53171569-04149D38-100C-4015-A99E-28B90AC4DA43Q54977379-F374B1DD-F5A5-4A1D-A634-D9413A39704EQ55434707-5BA03B55-05CB-45C3-A180-23654F19A054
P2860
MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
MKP1/CL100 controls tumor grow ...... in non-small-cell lung cancer.
@en
type
label
MKP1/CL100 controls tumor grow ...... in non-small-cell lung cancer.
@en
prefLabel
MKP1/CL100 controls tumor grow ...... in non-small-cell lung cancer.
@en
P2093
P356
P1433
P1476
MKP1/CL100 controls tumor grow ...... in non-small-cell lung cancer
@en
P2093
Chattopadhyay S
Gonzalez-Barón M
Machado-Pinilla R
Manguan-García C
Moratilla C
de Castro-Carpeño J
P2888
P304
P356
10.1038/SJ.ONC.1209364
P407
P577
2006-02-06T00:00:00Z
P5875
P6179
1005662112